ACE2 and COVID-19: Furthermore, due to downregulation of membrane‐bound ACE2 in COVID‐19 patients (Banu et al., 2020) and thus downregulation of the ACE2/ANG‐(1‐7)/MAS‐axis, ANG‐(1‐7)‐analogues are targets for therapy.